Ricevi le ultime notizie sulle azioni iBio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di IBIO

Ultime notizie per

IBIO INC

iBio

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

iBio Inc

Health Care

Press Releases

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

News

General

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Announces Proposed Public Offering

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Closing of $50 Million Public Offering

Earnings

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

IBIO

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Aptevo Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

enGene Holdings

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Kairos Pharma

Lunai Bioworks

Leap Therapeutics

Lisata Therapeutics

Moleculin Biotech

MetaVia

Nanoviricides

NextCure

Passage Bio

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Rallybio

SAB Biotherapeutics

Synlogic

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

Oppenheimer

Leerink Partners

Chardan Capital

LUCID CAPITAL MARKETS

Brookline Capital

Comments

iBio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO